# US 12,178,868 B2 · Immunogenic compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,868 B2
- Document ID: US12178868B2
- Status: Granted
- Kind: B2
- Application number: 18/476,042
- Filed: 2023-09-27
- Published: 2024-03-28
- Granted: 2024-12-31
- Earliest claimed: 2015-03-25
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Maria A. Croyle; Stephen Clay Schafer
- Web page: https://patentgrep.com/patent/US12178868B2

## CPC

- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 2039/543: {intranasal}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10351: Methods of production or purification of viral material
- C12N 2710/10371: Demonstrated in vivo effect
- C12N 2760/14134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.

## Claims

### Claim 1

A method of delivering a viral vector to a subject comprising, administering a composition comprising poly (maleic anhydride-alt-1 octadecene) and the viral vector to the subject, wherein the composition is in liquid form.

### Claim 2 (depends on 1)

The method of claim 1, wherein the poly (maleic anhydride-alt-1 octadecene) is substituted with 3-(dimethylamino) propylamine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition further comprises a water soluble polymer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition further comprises a salt.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition further comprises a sugar or sugar derivative.

### Claim 6 (depends on 5)

The method of claim 5, wherein the sugar or sugar derivative is selected from group consisting of: glucose, dextrose, fructose, lactose, maltose, xylose, sucrose, corn sugar syrup, sorbitol, hexitol, maltilol, xylitol, mannitol, melezitose, raffinose, and combinations thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is administered orally to the subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is formed by dispersing the viral vector within a solution of poly (maleic anhydride-alt-1 octadecene) at ambient temperatures to form a mixture.

### Claim 9 (depends on 1)

The method of claim 1, wherein the viral vector encodes a heterologous polypeptide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the viral vector is an adenovirus viral vector.

### Claim 11 (depends on 1)

The method of claim 1, wherein the viral vector is present in an amount of from about 1×106 to about 1×1013 virus particles.